bioRxivImmunologyPreprint
Functional immune mapping with deep-learning enabled phenomics applied to immunomodulatory and COVID-19 drug discovery
M. F. Cuccarese, B. A. Earnshaw, K. Heiser, B. Fogelson, C. T. Davis, P. F. McLean, H. B. Gordon, K.-R. Skelly, F. L. Weathersby, V. Rodic, I. K. Quigley, E. D. Pastuzyn, B. M. Mendivil, N. H. Lazar, C. A. Brooks, J. Carpenter, B. L. Probst, P. Jacobson, S. W. Glazier, J. Ford, J. D. Jensen, N. D. Campbell, M. A. Statnick, A. S. Low, K. R. Thomas, , C. C. Gibson
Abstract
Development of accurate disease models and discovery of immune-modulating drugs is challenged by the immune systems highly interconnected and context-dependent nature. Here we apply deep-learning-driven analysis of cellular morphology to develop a scalable "phenomics" platform and demonstrate its ability to identify dose-dependent, high-dimensional relationships among and between immunomodulators, toxins, pathogens, genetic perturbations, and small and large molecules at scale. High-throughput screening on this platform demonstrates rapid identification and triage of hits for TGF-{beta}- and TNF--driven phenotypes. We deploy the platform to develop phenotypic models of active SARS-CoV-2 infection and of COVID-19-associated cytokine storm, surfacing compounds with demonstrated clinical benefit and identifying several new candidates for drug repurposing. The presented library of images, deep learning features, and compound screening data from immune profiling and COVID-19 screens serves as a deep resource for immune biology and cellular-model drug discovery with immediate impact on the COVID-19 pandemic.
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- A deep learning-based drug repurposing screening and validation for anti-SARS-CoV-2 compounds by targeting the cell entry mechanism
- A phenomics approach for in vitro antiviral drug discovery
J. Rietdijk, M. Tampere, … J. Carreras-Puigvert·bioRxiv·Jan 13, 2021
- Identification of potential treatments for COVID-19 through artificial intelligence-enabled phenomic analysis of human cells infected with SARS-CoV-2
Katie Heiser, Peter McLean, … Christopher C. Gibson·bioRxiv·Apr 21, 2020
- Morphological cell profiling for drug repurposing against SARS-CoV-2 infection
Elin Asp, Jonne Rietdijk, … Päivi Östling·bioRxiv·Aug 28, 2025
- Data-driven analysis of COVID-19 reveals specific severity patterns distinct from the temporal immune response
J. Lim, G. Carissimo, … B. Lee·bioRxiv·Feb 10, 2021
- Deep immune profiling of COVID-19 patients reveals patient heterogeneity and distinct immunotypes with implications for therapeutic interventions
D. Mathew, J. R. Giles, … E. J. Wherry·bioRxiv·May 20, 2020